Neuropace, Inc. is a commercial-stage medical device company focused on treating epilepsy. Its primary product is the RNS System, a brain-responsive neuromodulation device that monitors brain electrical activity and delivers personalized, real-time stimulation to prevent seizures. The system is indicated in the United States for adults with drug-resistant focal epilepsy. The company serves patients through comprehensive epilepsy centers and qualified clinicians, including epileptologists and functional neurosurgeons. Neuropace holds investigational device exemption approval for clinical trials evaluating the RNS System for drug-resistant idiopathic generalized epilepsy and for patients aged 12 to 17. The company generates recurring revenue from the sale of replacement neuromodulation devices. Neuropace is exploring potential applications for other brain disorders, including depression, memory disorders, and post-traumatic stress disorder.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage neuropace.com
Sector Healthcare IR page investors.neuropace.com/overview/default.aspx
Tags
neuromodulation, epilepsy treatment, brain-responsive therapy, implantable devices, seizure management, eeg monitoring, functional neurosurgery, drug-resistant epilepsy, RNS System
Press page neuropace.com/about-neuropace/press-releases

Metrics

Valuation  
Market cap $ 285.54M
Market cap (USD) $ 285.54M
P/E -14.81
PEG —
P/BV 24.85
P/S 3.02
P/OCF -23.68
P/FCF -23.00
Dividend yield —
Turnover / mcap —
Returns  
ROE -158.7%
ROI -27.5%
ROIC -15.7%
Profit margin -21.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 514.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 27
Quality score -23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 99.986M 79.906M 65.421M 45.52M 45.183M 41.138M
Net profit -21.465M -27.141M -32.956M -47.082M -36.08M -24.278M
Free cash flow -11.338M -18.255M -19.874M -37.472M -24.961M -21.671M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 15.44 11.19 10.31 1.49 10.08 —
Price performance 12m 0.38 0.09 5.92 -0.85 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 8.4M 7.09M 7.48M 12.3M 12.9M 14.7M
↳ YoY growth -15.5% +5.5% +64.6% +4.4% +14.2%
↳ 5y CAGR +11.8%
Borrowings, current (USD) — 2.04M 0.00 — — — —
Borrowings, non-current (USD) — 50.8M 49.8M 52.9M 57M 59.5M 58.9M
Lease liabilities (USD) — — 0.00 16.9M 15.4M 13.8M 12M
Cash and deposits (USD) 4.12M 26.4M 19.2M 6.61M 18.1M 13.4M 21.7M
Right-of-use assets (USD) — — 0.00 14.8M 13.4M 11.8M 10.1M
Net debt (borrowings + leases - cash) (USD) — 26.5M 30.7M 63.2M 54.3M 59.9M 49.1M
Cash flow detail
Operating cash flow (USD) — -21.6M -24.6M -36.9M -19.7M -17.9M -11M
Purchases of property, plant and equipment (USD) — -62,000 -384,000 -603,000 -173,000 -306,000 -332,000
Change in receivables (cash effect) (USD) — -2.38M 1.3M -391,000 -4.85M -537,000 -1.83M
Change in inventories (cash effect) (USD) — 672,000 -1.16M -2.13M -1.7M -2.42M -3.67M
Change in payables (cash effect) (USD) — -5,000 479,000 647,000 240,000 671,000 -730,000
Share buybacks (cash effect) (USD) — — — — — 0.00 -49.5M
Interest paid (cash effect) (USD) — -4.41M -6.34M -4.46M -4.48M -6.23M -6.2M
Share-based compensation (USD) — 1.38M 4.29M 8.35M 9.56M 10.3M 11.1M
Operating cash flow before change in receivables (USD) — -19.2M -25.9M -36.5M -14.9M -17.4M -9.18M
Free cash flow (OCF - PPE - intangibles) (USD) — -21.7M -25M -37.5M -19.9M -18.3M -11.3M
Income detail
Research and development expense (USD) — 15.7M 18.2M 21.9M 20.8M 23.7M 27.9M
↳ 5y CAGR +12.2%
Total comprehensive income (USD) — -24.2M -36.4M -47.9M -33M — —
Comprehensive income to owners (USD) — -24.2M -36.4M -47.9M -33M — —
Reported Jun 3, 2021 Mar 10, 2022 May 12, 2022 Mar 2, 2023 Mar 5, 2024 Mar 3, 2026 Mar 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Q3 2026 total revenue of $23.1 million, including $22.9 million in RNS revenue representing 1% growth

Revises full year 2026 revenue guidance to $91 million to $92 million; focused on improving commercial execution and accelerating growth

Advances innovation pipeline with NeuroPace Remote Care™ FDA submission and upcoming IGE PMA-S Amendment, supporting significant long-term growth opportunities

Mountain View, Calif. – November 12, 2026 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

October 29, 2026

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2026 after market close on Thursday, November 12, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Investors interested in listening to the conference call may do so by accessing a live webcast of the event here . Individuals interested in participating in the call via telephone may access the call by dialing +1 833-461-5787 and referencing Conference ID 345 741 415. The webcast will be archived on the company’s investor relations website at https://investors.neuropace.com/news-and-events/events and will be available for replay for at least 90 days after the event.

About NeuroPace, Inc.

Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Investor Contact:
Scott Schaper
Head of Investor Relations
[email protected]

[email protected]

Source: NeuroPace, Inc.

View All News

NeuroPace, Inc., logo

Follow us

X logo    Facebook logo    Linkedin logo    Youtube    Instagram logo

IR Contacts

Scott Schaper
Head of Investor Relations
[email protected]

Investor Email Alerts

Personal Information.

Email Address *Required Email Address is required. Email Address is invalid.

Investor Alert Options *

  • News
  • Quarterly Reports
  • Annual Reports
  • SEC Filings
  • End of Day Stock Quote
  • Events & Presentations

Investor Alert Options is required.

The captcha test has failed. Please try again.

Submit

Unsubscribe

© 2026 NeuroPace, Inc. - All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

September 1, 2026

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global Healthcare Conference.

NeuroPace management will participate in a fireside chat discussion on Wednesday, September 9 at 10:55am EDT, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via a live webcast here and a replay will be available on the Events section of NeuroPace’s Investor website at https://investors.neuropace.com/news-and-events/events .

About NeuroPace, Inc.

Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Investor Contact:
Scott Schaper
Head of Investor Relations
[email protected]

[email protected]

Source: NeuroPace, Inc.

View All News

NeuroPace, Inc., logo

Follow us

X logo    Facebook logo    Linkedin logo    Youtube    Instagram logo

IR Contacts

Scott Schaper
Head of Investor Relations
[email protected]

Investor Email Alerts

Personal Information.

Email Address *Required Email Address is required. Email Address is invalid.

Investor Alert Options *

  • News
  • Quarterly Reports
  • Annual Reports
  • SEC Filings
  • End of Day Stock Quote
  • Events & Presentations

Investor Alert Options is required.

The captcha test has failed. Please try again.

Submit

Unsubscribe

© 2026 NeuroPace, Inc. - All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

Prompts

Neuropace, Inc. (ticker NPCE), listed in United States.

ETFs Holding Neuropace, Inc.

ETF Weight in ETF Shares Market value As of
SYZ 0.15% 6,473 $ 102.856K Jun 30, 2026
OASC 0.15% 9,307 $ 136.348K Aug 31, 2026
FSEG 0.10% 358 $ 5,688.62 Jun 30, 2026
FEAC 0.05% 805 $ 12.791K Jun 30, 2026